ESTROGEN ANCHORED NANOMICELLES FOR COMBINATIONAL DRUG DELIVERY WITH ENHANCED THERAPEUTIC EFFICACY: A PROTEOMICS GUIDED INVESTIGATION FOR MULTIFUNCTIONAL NANOTHERAPEUTICS
The employment of the stable isotope labeling with amino acids in cell culture (SILAC) based proteomic analysis as a guidance tool for investigation of cellular response of a multifunctional nanodelivery system has been described for cancer therapy. The multifunctional nanodelivery system in this study was based on an estrogen anchored multimodal nanomicelle (NPG). The key components of the multifunctional nanomicelle consist: Î²-cyclodextrin conjugated estrone (CDE1), an escort molecule; polymeric BH3 mimetic, a proapoptotic BcL-2 inhibitor; and the mitotic catastrophe agent paclitaxel. They were assembled into the nanomicelle by multiple weak interactions including hydrophobic/hydrophilic interaction and host-guest recognition. The resulting nanomicelle exhibited unimodal morphology with average size of 170 nm with sustained release. It was found that the nanoparticle exhibits excellent anti-tumor activities for the treatment of breast adenocarcinoma with exceptional targeting efficacy both in MCF-7 tumor bearing mice. NPG as a new drug delivery system demonstrated several merits such as the increased drug uptake in breast tumor tissue, low toxicity, potent tumor growth retardation and metastasis inhibition, as well as potential clinical practicality without compromising liver, kidney and immune function and ameliorating the conventional chemotherapeutics induced phlebitis in breast tumor bearing nude mice model. The systematic SILAC based proteomics study and the subsequent validation revealed that the synergistic induction of mitotic catastrophe through enhanced G2/M phase arrest and PI3K/Akt/mTOR mediated autophagy, account for the exceedingly potent anti-tumor activity of this convergent nanomicelle. Additionally, the verification of the top upregulated gene from the proteomics profiling revealed that the overexpression of zinc finger protein 350 (ZNF350/ZBRK1) is associated with the enhanced antitumor effect induced by NPG.
KEYWORDS:Â Drug targeting, Estrogen Receptor, Proteomics, Paclitaxel, Gossypol, Synergism
2 Hu CM, Aryal S, Zhang L, Ther Deliv. 2010; 1:323-34.
3 Liao L, Liu J, Dreaden EC, Morton SW, Shopsowitz KE, Hammond PT, Johnson JA, Journal of the American Chemical Society. 2014; 136:5896-5899
4 Huang P, Wang D, Su Y, Huang W, Zhou Y, Cui D, Zhu X, Yan D, Journal of the American Chemical Society. 2014; 136:11748-11756
5 Markovsky E, Baabur-Cohen H, Satchi-Fainaro R, Journal of Controlled Release. 2014; 187:145-157.
6 Ma L, Kohli M, Smith A, Acs Nano. 2013; 7:9518-9525.
7 Manzoor AA, Lindner LLH, Landon CD, Park JY, Simnick AJ, Dreher MR, Das S, Hanna G, Park W, Chilkoti A, Koning GA, Ten Hagen TL, Needham D, Dewhirst MW, Cancer Res. 2012; 72:5566-75.
8 Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M, Molecular & Cellular Proteomics. 2002; 1:376-386.
9 Ong SE, Mann M, Nat Chem Biol. 2005; 1:252-262.
10 Verano-Braga T, Miethling-Graff R, Wojdyla K, Rogowska-Wrzesinska A, Brewer JR, Erdmann H, Kjeldsen F, ACS Nano. 2014; 8:2161-2175.
11 Hofmann D, Tenzer S, Bannwarth MB, Messerschmidt C, Glaser S-F, Schild H, Landfester K, MailÃ¤nder V, ACS Nano. 2014; 8:10077-10088
12 Kelly MJ, Levin ER, Trends Endocrinol Metab. 2001; 12:152-6
13 Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z, J Biol Chem. 2012; 287:7169-81
14 Li L, Haynes MP, Bender JR, Proc Natl Acad Sci U S A. 2003; 100:4807-12
15 M. Kampa, G. Notas, V. Pelekanou, M. Troullinaki, M. Andrianaki, K. Azariadis, E. Kampouri, K. Lavrentaki, and E. Castanas, Steroids. 2012; 77:959-67
16 Micevych PE, Kelly MJ, Neuroendocrinology. 2012; 96:103-10
17 Jordan MA, Wilson L, Nature Reviews Cancer. 2004; 4:253-265
18 Oliver CL, Bauer JA, Wolter KG, Clinical Cancer Research. 2005; 11:5659-5659
19 Yin JJ, Sharma S, Shumyak SP, Wang ZX, Zhou ZW, Zhang Y, Guo P, Li CZ, Janwar JR, Yang T, Mohapatra SS, Liu W, Duan W, Wang JC, Li Q, Zhang X, Tan J, Jia L, Liang J, Wei MQ, Li X, Zhou SF, PLoS One. 2013; 8:e62289
20 Torchilin VP, Pharmaceutical Research. 2007; 24:1-16
21 Lin L-F, Chuang C-H, Li C-F, Liao C-C, Cheng C-P, Cheng T-L, Shen M-R, Tseng JT, Chang W-C, Lee W-H, Wang J-M, Cancer Research. 2010; 70:192-201
22 Rutter JL, Smith AM, Davila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, M. Tucker A, Greene MH, Zhang JH, Struewing JP, Human Mutation. 2003; 22:121-128
23 Swami M, Nat Rev Cancer. 2010; 10:597-597.
24 Cox J, Mann M, Nat Biotechnol. 2008; 26:1367-72
25 Veldhoen RA, Banman SL, Hemmerling DR, Odsen R, Simmen T, Simmonds AJ, Underhill DA, Goping IS, Oncogene. 2013; 32:736-746
26 Kang R, Zeh HJ, Lotze MT, Tang D, Cell Death and Differentiation. 2011; 18:571-580
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).